To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

June 26, 2018

Today's Rundown

Featured Story

Roivant cuts staff, reassigns others in major reshuffle, as insider decries 'bloodbath'

Roivant has laid off some staff and reassigned others to subsidiaries in a notable strategic shift. The changes see Roivant shed around 10% of its staff and cede responsibility for others to the heads of its portfolio of startups.

Top Stories

AbbVie and Calico renew their aging research collaboration with an extra $1B

AbbVie and Calico are reupping their massive, $1.5 billion research collaboration on age-related diseases first launched in 2014, with a new billion-dollar commitment split between the two.

Precision BioSciences bags $110M to take off-the-shelf CAR-T into humans

Precision BioSciences has raised $110 million. The series B round sets the genome editing specialist up to take its lead, off-the-shelf CAR-T therapy into clinical trials.

[Sponsored] The Growing Need for Data Management Solutions in Clinical Labs

The increasing demand for innovation in research and the related pressures to deliver on the most promising findings from discovery are also driving the need for simultaneous innovation in the technologies that enable that innovation and, likewise, the reliance on data management solutions that respond to an increasingly complex scientific environment.

Dementia Discovery Fund reels in $350M for disease-modifying drugs

The Dementia Discovery Fund capped its fundraising at $350 million; it was nudged across the line by a $60 million investment from AARP.

Celgene inks $60M deal with newcomer Skyhawk to develop RNA drugs for ALS, Huntington’s

Celgene launched a $60 million collaboration with Skyhawk Therapeutics to develop and commercialize small molecules targeting RNA mis-splicing in neurological diseases.

Kaleido brings in $101M in series C for its microbiome-wide therapy pipeline

Kaleido Biosciences has raked in $101 million in series C financing, after coming out of stealth last September with $65 million, with the goal of developing novel chemistries that direct the human microbiome and its various bacteria as a whole.

BrainStorm backs down from providing ALS treatment under right-to-try

BrainStorm Cell Therapeutics has decided not to offer its experimental cell therapy for amyotrophic lateral sclerosis (ALS) under the newly passed law. The Israeli biotech considered ethical, legal and practical aspects of providing the treatment and said the clincher was its inability to fund the treatment for all patients who wanted to try it.

Enrollment Showcase

SBMI Now Offering an Online Graduate Program in Bioinformatics

UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics.

Resources

[Survey] 2018 eClinical Technology Solutions Survey

Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now!

[Whitepaper] Is the pharma business model ready for precision medicine?

Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare.

[Whitepaper] Implementing a Proactive Approach to Risk Management

A solid RBM plan will not only help you comply with the ICH guidelines, but will help you mitigate risks which could ultimately delay your trials and increase costs. Download today!

[Whitepaper] Getting to First-in-Human Clinical Trials: A Make-or-Break Milestone for Small Biopharmas

“Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure.

[Whitepaper] Compliance Certificate and Training for Life Sciences Professionals

4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics.

[Whitepaper] Digitizing the Global Life Sciences Supply Chain: The Critical Role of Digital Transaction Management

Life science companies are experiencing a significant transformation in how they bring new products to market.

Events

.